Identifying new therapeutic targets via modulation of protein corona formation by engineered nanoparticles

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Arvizo, Rochelle R ^a   Giri, Karuna ^a   Moyano, Daniel ^b   Miranda, Oscar R ^b   Madden, Benjamin ^c   McCormick, Daniel J ^c   Bhattacharya, Resham ^a   Rotello, Vincent M ^b   Kocher, Jean Pierre ^c   Mukherjee, Priyabrata ^a,d  

^a MAYO GRADUATE SCHOOL   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

^c Mayo Clinic College of Medicine   (United States)

^d MAYO CLINIC CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GOLD NANOPARTICLE; HEPATOMA DERIVED GROWTH FACTOR; PROTEIN; PROTEIN CORONA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; BIOMATERIAL; GOLD; HEPATOMA-DERIVED GROWTH FACTOR; METAL NANOPARTICLE; SIGNAL PEPTIDE; TUMOR PROTEIN;

ARTICLE; BIOENGINEERING; CANCER CELL; CELL LYSATE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MASS SPECTROMETRY; OVARY CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN LOCALIZATION; PROTEIN RNA BINDING; PROTEIN STRUCTURE; PROTEIN TARGETING; PROTEOMICS; STRUCTURAL HOMOLOGY; WESTERN BLOTTING; BIOSYNTHESIS; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECT; FEMALE; GENE SILENCING; METABOLISM; OVARY TUMOR; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; COATED MATERIALS, BIOCOMPATIBLE; FEMALE; GENE SILENCING; GOLD; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; METAL NANOPARTICLES; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; RNA, SMALL INTERFERING;

EID: 84858591058     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033650     Document Type: Article

References (50)

1. Rana S, Bajaj A, Mout R, Rotello VM, (2011) Monolayer coated gold nanoparticles for delivery applications. Adv Drug Delivery Rev doi:10.1016/j.addr.2011.08.006.
2. Arvizo RR, Rana S, Miranda OR, Bhattacharya R, Rotello VM, et al. (2011) Mechanism of anti-angiogenic property of gold nanoparticles: role of nanoparticle size and surface charge. Nanomed Nanotechnol Biol Med 7: 580-587.
3. Dobrovolskaia MA, McNeil SE, (2007) Immunological properties of engineered nanomaterials. Nat Nanotechnol 2 (8): 469-478.
4. Petros RA, DeSimone J, (2010) Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discovery 9 (8): 615-627.
5. Liang M, Lin IC, Whittaker MR, Minchin RF, Monteiro MJ, et al. (2009) Cellular Uptake of Densely Packed Polymer Coatings on Gold Nanoparticles. ACS Nano 4 (1): 403-413.
6. Karmali PP, Simberg D, (2011) Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems. Expert Opin Drug Delivery 8 (3): 343-357.
7. Aggarwal P, Hall JB, McLeland CB, Dobrovolskaia MA, McNeil SE, (2009) Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Delivery Rev 61 (6): 428-437.
8. Ehrenberg MS, Friedman AE, Finkelstein JN, Oberderster GN, McGrath JL, (2009) The influence of protein adsorption on nanoparticle association with cultured endothelial cells. Biomaterials 30 (4): 603-610.
9. Dobrovolskaia MA, Germolec D, Weaver JL, (2009) Evaluation of nanoparticle immunotoxicity. Nat Nanotechnol 4 (7): 411-414.
10. De M, Rana S, Akpinar H, Miranda OR, Arvizo RR, et al. (2009) Sensing of proteins in human serum using conjugates of nanoparticles and green fluorescent protein. Nat Chem 1 pp. 461-465.
11. Monopoli MP, Walczyk D, Lowry-Campbell A, Elia G, Lynch I, et al. (2011) Physical-Chemical Aspects of Protein Corona: Relevance to in Vitro and in Vivo Biological Impacts of Nanoparticles. J Am Chem Soc 133 (8): 2525-2534.
12. Sund J, Alenius H, Vippola M, Savolainen K, Puustinen A, (2011) Proteomic Characterization of Engineered Nanomateria, Protein Interactions in Relation to Surface Reactivity. ACS Nano 5 (6): 4300-4309.
13. Conover CA, Hartmann LC, Bradley S, Stalboerger P, Klee GG, et al. (1998) Biological Characterization of Human Epithelial Ovarian Carcinoma Cells in Primary Culture: The Insulin-like Growth Factor System. Exp Cell Res 238 (2): 439-449.
14. Kruk PA, Maines- Bandiera SL, Auersperg N, (1990) A simplified method to culture human ovarian surface epithelium. Lab Invest 63: 132-136.
15. Tenzer S, Docter D, Rosfa S, Wlodarski A, Kuharev J, et al. (2011) Nanoparticle Size Is a Critical Physicochemical Determinant of the Human Blood Plasma Corona: A Comprehensive Quantitative Proteomic Analysis. ACS Nano 5 (9): 7155-7167.
16. Ruiz van Haperen VW, Veerman G, Eriksson S, Boven E, Stegmann APA, et al. (1994) Development and Molecular Characterization of a 2′,2′-Difluorodeoxycytidine-resistant Variant of the Human Ovarian Carcinoma Cell Line A2780. Cancer Research 54 (15): 4138-4143.
17. Willmott LJ, Fruehauf JP, (2010) Targeted Therapy in Ovarian Cancer. J Oncol 2010.
18. Jasen P, (2009) From the "Silent Killer" to the "Whispering Disease": Ovarian Cancer and the Uses of Metaphor. Med Hist 53 (4): 489-512.
19. Bast RC, (2003) Status of Tumor Markers in Ovarian Cancer Screening. Journal of Clinical Oncology 21 (10 suppl): 200-205.
20. Yap T, Carden C, Kay SB, (2009) Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 9 (3): 167-181.
21. Gilchrist A, Au CE, Hiding J, Bell AW, Fernandez-Rodriguez J, et al. (2006) Quantitative Proteomics Analysis of the Secretory Pathway. Cell 127 (6): 1265-1281.
22. Bergeron JJM, Au CE, Desjardins M, McPherson PS, Nilsson T, (2005) Cell biology through proteomics. Trends Cell Biol 20 (6): 337-345.
23. Rifai N, Gilette M, Carr SA, (2006) Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotech 24 (8): 971.
24. Dhingra V, Gupta M, Andacht T, Fu ZF, (2005) New frontiers in proteomics research: A perspective. Int J Pharm 299 (1-2): 1-18.
25. Aebersold R, Mann M, (2003) Mass spectrometry-based proteomics. Nature 422 (6928): 198-207.
26. Bantscheff M, Schirle M, Sweetman G, Rick J, Kuster B, (2007) Quantitative mass spectrometry in proteomics: a critical review. Anal Bioanal Chem 389 (4): 1017-1031.
27. Keshishian H, Addona T, Burgess M, Kuhn E, Carr SA, (2007) Quantitative, Multiplexed Assays for Low Abundance Proteins in Plasma by Targeted Mass Spectrometry and Stable Isotope Dilution. Anal Bioanal Chem 6 (12): 2212-2229.
28. Tang H-Y, Ali-Khan N, Echan LA, Levenkova N, Rux JJ, et al. (2005) A novel four-dimensional strategy combining protein and peptide separation methods enables detection of low-abundance proteins in human plasma and serum proteomes. Proteomics 5 (13): 3329-3342.
29. Diamandis EP, (2004) Analysis of Serum Proteomic Patterns for Early Cancer Diagnosis: Drawing Attention to Potential Problems. Jour Nat Cancer Inst 96 (5): 353-356.
30. Jung S-Y, Lim S-M, Albertorio F, Kim G, Gurau MC, et al. (2003) The Vroman Effect: A Molecular Level Description of Fibrinogen Displacement. J Am Chem Soc 125 (42): 12782-12786.
31. Monopoli MP, Walczyk D, Campbell A, Elia G, Lynch I, et al. (2011) Physical-Chemical Aspects of Protein Corona: Relevance to in Vitro and in Vivo Biological Impacts of Nanoparticles. J Am Chem Soc 133 (8): 2525-2534.
32. Liu S, Han Y, Qiao R, Zeng J, Jia Q, et al. (2010) Investigations on the Interactions between Plasma Proteins and Magnetic Iron Oxide Nanoparticles with Different Surface Modifications. J Phys Chem C 114 (49): 21270-21276.
33. Lundqvist M, Stigler J, Elia G, Lunch I, Cedervall T, et al. (2008) Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci U S A.
34. Deng ZJ, Liang M, Monteiro M, Toth I, Minchin RF, (2011) Nanoparticle-induced unfolding of fibrinogen promotes Mac-1 receptor activation and inflammation. Nature Nanotechnol 6 (1): 39-44.
35. Deng ZJ, Mortimer G, Schiller T, Musumeci A, Martin D, et al. (2009) Differential plasma protein binding to metal oxide nanoparticles. Nanotechnology 20 (45): 455101.
36. Lundqvist M, Stigler J, Cedervall T, Berggard T, Flanagan MB, et al. (2011) The Evolution of the Protein Corona around Nanoparticles: A Test Study. ACS Nano 5 (9): 7503-7509.
37. Law W-C, Yong K-T, Baev A, Prasad PN, (2011) Sensitivity Improved Surface Plasmon Resonance Biosensor for Cancer Biomarker Detection Based on Plasmonic Enhancement. ACS Nano 5 (6): 4858-4864.
38. Liu X, Qiu D, Austin L, Coutts J, Knowles G, et al. (2008) A One-Step Homogeneous Immunoassay for Cancer Biomarker Detection Using Gold Nanoparticle Probes Coupled with Dynamic Light Scattering. J Am Chem Soc 130 (9): 2780-2782.
39. Huo Q, Colon J, Cordero A, Bogdanovic J, Baker C, et al. (2011) A Facile Nanoparticle Immunoassay for Cancer Biomarker Discovery. J Nanobiotechnol 9 (1): 20.
40. Tsang T, Tang W, Tsang W, Co N, Kong S, et al. (2008) Downregulation of hepatoma-derived growth factor activates the Bad-mediated apoptotic pathway in human cancer cells. Apoptosis 13 (9): 1135-1147.
41. Lee KH, Choi EY, Kim MK, Lee SH, Jang BI, et al. (2010) Hepatoma-derived growth factor regulates the bad-mediated apoptotic pathway and induction of vascular endothelial growth factor in stomach cancer cells. Oncol Res 19 (2): 67-76 (in eng).
42. Zhang J, Ren H, Yuan P, Lang W, Zhang L, et al. (2006) Down-regulation of Hepatoma-Derived Growth Factor Inhibits Anchorage-Independent Growth and Invasion of Non-Small Cell Lung Cancer Cells. Cancer Res 66 (1): 18-23.
43. Everett AD, Lobe DR, Matsumura ME, Nakamura H, McNamara CA, (2000) Hepatoma-derived growth factor stimulates smooth muscle cell growth and is expressed in vascular development. J Clin Invest 105 (5): 567-575.
44. You C-C, De M, Rotello VM, (2005) Contrasting effects of exterior and interior hydrophobic moieties in the complexation of amino acid functionalized gold clusters with alpha-chymotrypsin. Org Lett 7: 5685-5688.
45. Brust M, Walker M, Bethell D, Schiffrin DJ, Whyman RJ, (1994) Synthesis of Thiol-derivatised Gold Nanoparticles in a Two-phase Liquid-Liquid System. J Chem Soc., Chem Commun 7 (7): 801-802.
46. Hostetler MJ, Templeton AC, Murray RW, (1999) Dynamics of Place-Exchange Reactions on Monolayer-Protected Gold Cluster Molecules. Langmuir 15 (11): 3782-3789.
47. Hong R, Fernandez JM, Nakade H, Arvizo R, Emrick T, et al. (2006) In situ observation of place exchange reactions of gold nanoparticles. Correlation of monolayer structure and stability. Chem Commun pp. 2347-2349.
48. Olsen JV, de Godoy, Lyris MF, Li G, Macek B, et al. (2005) Parts per Million Mass Accuracy on an Orbitrap Mass Spectrometer via Lock Mass Injection into a C-trap. Mol Cell Proteomics 4 (12): 2010-2021.
49. Keller A, Nesvizhskii AI, Kolker E, Aebersold R, (2002) Empirical Statistical Model To Estimate the Accuracy of Peptide Identifications Made by MS/MS and Database Search. Anal Chem 74 (20): 5383-5392.
50. Nesvizhskii AI, Keller A, Kolker E, Aebersold R, (2003) A Statistical Model for Identifying Proteins by Tandem Mass Spectrometry. Anal Chem 75 (17): 4646-4658.